{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:24:39Z","timestamp":1791217479224,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.jaad.2005.02.011","type":"journal-article","created":{"date-parts":[[2005,7,14]],"date-time":"2005-07-14T10:59:21Z","timestamp":1121338761000},"page":"291-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["The promise of molecular targeted therapies: Protein kinase inhibitors in the treatment of cutaneous malignancies"],"prefix":"10.1016","volume":"53","author":[{"given":"Lavanya","family":"Kondapalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyoumars","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2005.02.011_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2005.02.011_bib2","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jaad.2005.02.011_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003495-200059030-00004","article-title":"Kinase inhibitors in cancer therapy: a look ahead","volume":"59","author":"Sedlacek","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2005.02.011_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0960-7404(03)00004-5","article-title":"A decade of tyrosine kinases: from gene discovery to therapeutics","volume":"12","author":"Craven","year":"2003","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib5","first-page":"357","article-title":"Assay and screening methods for bioactive substances based on cellular signaling pathways","volume":"82","author":"Umezawa","year":"2002","journal-title":"J Biotechnol"},{"key":"10.1016\/j.jaad.2005.02.011_bib6","unstructured":"US Food and Drug Administration. CDER new and generic drug approvals: 1998-2004. Available from: http:\/\/www.fda.gov\/cder\/approval\/. Accessed October 1, 2004."},{"key":"10.1016\/j.jaad.2005.02.011_bib7","unstructured":"National Institutes of Health. Search results for kinase and cancer. Available from: http:\/\/www.clinicaltrials.gov\/ct\/search;jsessionid=72A4470DFD89457ADC8371A6A4D83FE8?term=kinase+and+cancer&submit=Search. Accessed September 24, 2004."},{"key":"10.1016\/j.jaad.2005.02.011_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrd1066","article-title":"Issues and progress with protein kinase inhibitors for cancer treatment","volume":"2","author":"Dancey","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2005.02.011_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signaling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2005.02.011_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00008390-200010000-00001","article-title":"Protein tyrosine kinases in malignant melanoma","volume":"10","author":"Easty","year":"2000","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib11","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1101\/gad.1152403","article-title":"Opportunities and challenges in the development of kinase inhibitor therapy for cancer","volume":"17","author":"Sawyers","year":"2003","journal-title":"Genes Dev"},{"key":"10.1016\/j.jaad.2005.02.011_bib12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2005.02.011_bib13","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.jaad.2005.02.011_bib14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2005.02.011_bib15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2005.02.011_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000074470","article-title":"Gastrointestinal stromal tumors: biology and treatment","volume":"65","author":"Duffaud","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.jaad.2005.02.011_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.semcancer.2003.11.007","article-title":"Targets for molecular therapy of skin cancer","volume":"14","author":"Green","year":"2004","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jaad.2005.02.011_bib18","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib19","first-page":"710","article-title":"Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P)","volume":"22","author":"Flaherty","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib20","first-page":"679","article-title":"Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations","volume":"30","author":"Martinez","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2005.02.011_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jaad.2005.02.011_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000051637","article-title":"Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin","volume":"202","author":"Shimizu","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2005.02.011_bib23","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","article-title":"The EGF receptor family as targets for cancer therapy","volume":"19","author":"Mendelsohn","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2005.02.011_bib24","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1200\/jco.2004.22.90140.3047","article-title":"Clinical activity of GW572016 in EGF10003 in patients with solid tumors","volume":"22","author":"Versola","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib25","first-page":"243","article-title":"A phase I trial of CI-1033, a pan-erbB tyrosine kinase inhibitorm, given daily for 14 days every 3 weeks, in patients with advanced solid tumors","volume":"22","author":"Nemunaitis","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib26","first-page":"1236","article-title":"Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy","volume":"59","author":"Yang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib27","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1200\/jco.2004.22.90140.5502","article-title":"Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent\/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study","volume":"22","author":"Trigo","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib28","first-page":"4637","article-title":"Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts","volume":"53","author":"Fan","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib29","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/85.16.1327","article-title":"Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies","volume":"85","author":"Baselga","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2005.02.011_bib30","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib31","first-page":"1204","article-title":"Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer","volume":"7","author":"Shin","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib32","article-title":"Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy","author":"Hong","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib33","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1200\/jco.2004.22.90140.5541","article-title":"Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN)","volume":"22","author":"Rhoades","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib34","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1200\/jco.2004.22.90140.5539","article-title":"Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and\/or metastatic squamous cell carcinoma of the head and neck (SCCHN)","volume":"22","author":"Mauer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib35","first-page":"225","article-title":"Phase I and pharmacokinetic study of erlotonib HCL (E; OSI-774) in combination with capecitabine (C) in patients with advanced solid tumors","volume":"22","author":"Desai","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib36","first-page":"209","article-title":"Phase I, pharmacokinetic (PK) and biologic study of erlotinib (OSI-774) in combination with paclitaxel and carboplatin in advanced solid malignancies","volume":"22","author":"Mita","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib37","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2003.10.051","article-title":"Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"21","author":"Cohen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib38","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1200\/jco.2004.22.90140.5540","article-title":"Phase I study of gefitinib plus celecoxib in patients with metastatic and\/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN)","volume":"22","author":"Wirth","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib39","article-title":"A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT)","author":"Winquist","year":"2002","journal-title":"ASCO Annual Meeting"},{"key":"10.1016\/j.jaad.2005.02.011_bib40","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nature01283","article-title":"NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia","volume":"421","author":"Dajee","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2005.02.011_bib41","first-page":"61","article-title":"Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck","volume":"20","author":"Kies","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib42","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/nm779","article-title":"CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis","volume":"8","author":"Lazarov","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2005.02.011_bib43","unstructured":"National Institutes of Health. Flavopiridol in treating patients with metastatic or unresectable mantle cell lymphoma, chronic lymphocytic leukemia, multiple myeloma, mesothelioma, renal cell carcinoma (kidney cancer), squamous cell carcinoma of the head and neck, small cell lung cancer, or invasive breast cancer. Available from: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00070239?order=1. Accessed September 24, 2004."},{"key":"10.1016\/j.jaad.2005.02.011_bib44","unstructured":"National Institutes of Health. Flavopiridol for treating recurrent or metastatic head and neck cancer. Available from: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00005670?order=1. Accessed September 24, 2004."},{"key":"10.1016\/j.jaad.2005.02.011_bib45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.drup.2003.10.003","article-title":"Modulating protein kinase C (PKC) to increase the efficacy of chemotherapy: stepping into darkness","volume":"6","author":"Lorenzo","year":"2003","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.jaad.2005.02.011_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00001813-200201000-00011","article-title":"Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines","volume":"13","author":"Hoffmann","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jaad.2005.02.011_bib47","unstructured":"National Institutes of Health. Bryostatin 1 in treating patients with metastatic or recurrent head and neck cancer. Available from: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00003443? order=1. Accessed September 24, 2004."},{"key":"10.1016\/j.jaad.2005.02.011_bib48","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/sj.onc.1205225","article-title":"Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)","volume":"21","author":"Sato","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2005.02.011_bib49","unstructured":"National Institutes of Health. UCN-01 and irinotecan in treating patients with metastatic or unresectable solid tumors. Available from: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00031681?order=1. Accessed September 24, 2004."},{"key":"10.1016\/j.jaad.2005.02.011_bib50","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2005.02.011_bib51","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/417906a","article-title":"Lucky draw in the gene raffle","volume":"417","author":"Pollock","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2005.02.011_bib52","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2005.02.011_bib53","first-page":"708","article-title":"BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience","volume":"23","author":"Ahmad","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib54","first-page":"708","article-title":"Phase I\/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma","volume":"23","author":"Flaherty","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib55","first-page":"333","article-title":"Immunohistochemical detection of HER-2\/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas","volume":"24","author":"Potti","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib56","first-page":"51","article-title":"Loss of c-kit expression in cultured melanoma cells","volume":"7","author":"Lassam","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2005.02.011_bib57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.0022-202X.2004.22231.x","article-title":"Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo","volume":"122","author":"McGary","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2005.02.011_bib58","first-page":"713","article-title":"Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM)","volume":"23","author":"Eton","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib59","first-page":"713","article-title":"A phase II trial of imatinab mesylate at 800 mg daily in metastatic melanoma: lack of clinical efficacy with significant toxicity","volume":"22","author":"Wyman","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib60","first-page":"724","article-title":"Phase I trial of imatinib and temozolomide in patients with metastatic melanoma","volume":"23","author":"Schuchter","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib61","first-page":"2105","article-title":"The bryostatins inhibit growth of B16\/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1","volume":"56","author":"Szallasi","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib62","first-page":"682","article-title":"Successful treatment of murine melanoma with bryostatin 1","volume":"51","author":"Schuchter","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00688328","article-title":"Comparison of the antitumor activity of bryostatins 1, 5, and 8","volume":"37","author":"Kraft","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaad.2005.02.011_bib64","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/jnci\/85.22.1812","article-title":"Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The cancer research campaign phase I committee","volume":"85","author":"Philip","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2005.02.011_bib65","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00008390-200104000-00014","article-title":"Phase II evaluation of bryostatin-1 in metastatic melanoma","volume":"11","author":"Bedikian","year":"2001","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib66","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00008390-199912000-00010","article-title":"Treatment of patients with metastatic melanoma with bryostatin-1\u2014a phase II study","volume":"9","author":"Gonzalez","year":"1999","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib67","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/bjc.1998.680","article-title":"A phase II study of bryostatin 1 in metastatic malignant melanoma","volume":"78","author":"Propper","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2005.02.011_bib68","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1023\/A:1020694425356","article-title":"A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: a National Cancer Institute of Canada clinical trials group study","volume":"20","author":"Tozer","year":"2002","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2005.02.011_bib69","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1200\/JCO.2001.19.8.2319","article-title":"Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms","volume":"19","author":"Sausville","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib70","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1158\/0008-5472.CAN-03-3327","article-title":"Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase\/Akt and Raf\/mitogen-activated protein kinase kinase\/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice","volume":"64","author":"Bedogni","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib71","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00001622-200403000-00012","article-title":"New molecular targets in melanoma","volume":"16","author":"Flaherty","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib72","first-page":"712","article-title":"CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium","volume":"23","author":"Margolin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib73","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jnci\/91.5.446","article-title":"CDKN2A variants in a population-based sample of Queensland families with melanoma","volume":"91","author":"Aitken","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2005.02.011_bib74","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00008390-200306000-00002","article-title":"The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines","volume":"13","author":"Robinson","year":"2003","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib75","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1023\/B:DRUG.0000026258.02846.1c","article-title":"Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma","volume":"22","author":"Burdette-Radoux","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2005.02.011_bib76","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/1523-1747.ep12616793","article-title":"Increasing epidermal growth factor receptor expression in human melanocytic tumor progression","volume":"99","author":"de Wit","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2005.02.011_bib77","first-page":"209","article-title":"Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors","volume":"23","author":"Simon","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib78","first-page":"202","article-title":"A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer","volume":"23","author":"Erlichman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gcc.10202","article-title":"Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment","volume":"37","author":"Sirvent","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jaad.2005.02.011_bib80","first-page":"3719","article-title":"The dermatofibrosarcoma protuberans-associated collagen type I alpha 1\/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB","volume":"59","author":"Shimizu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib81","first-page":"830","article-title":"Response of metastatic dermatofibrosarcoma protuberans to imatinib mesylate","volume":"22","author":"Labropoulos","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib82","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1200\/JCO.2002.01.027","article-title":"Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans","volume":"20","author":"Rubin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib83","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ijc.10535","article-title":"Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans","volume":"100","author":"Maki","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaad.2005.02.011_bib84","unstructured":"National Institutes of Health. Imatinib mesylate in treating patients with locally advanced or metastatic dermatofibrosarcoma protuberans or giant cell fibroblastoma. Available from: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00085475?order=1. Accessed September 24, 2004."},{"key":"10.1016\/j.jaad.2005.02.011_bib85","unstructured":"National Institutes of Health. Imatinib mesylate in treating patients with locally recurrent or metastatic dermatofibrosarcoma protuberans (DFSP) or transformed fibrosarcomatous DFSP. Available from: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00084630?order=1. Accessed September 24, 2004."},{"key":"10.1016\/j.jaad.2005.02.011_bib86","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00000372-200208000-00001","article-title":"CD117 (KIT receptor) expression in Merkel cell carcinoma","volume":"24","author":"Su","year":"2002","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2005.02.011_bib87","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2133.2003.05779.x","article-title":"KIT receptor (CD117) expression in Merkel cell carcinoma","volume":"150","author":"Strong","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2005.02.011_bib88","first-page":"213","article-title":"Combined effect of aloe-emodin and chemotherapeutic agents on the proliferation of an adherent variant cell line of Merkel cell carcinoma","volume":"11","author":"Fenig","year":"2004","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jaad.2005.02.011_bib89","unstructured":"National Institutes of Health. Imatinib mesylate in treating patients with metastatic or unresectable merkel cell cancer. Available from: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00068783?order=2. Accessed January 4, 2005."},{"key":"10.1016\/j.jaad.2005.02.011_bib90","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/jso.20090","article-title":"Kaposi's sarcoma: an update","volume":"87","author":"Schwartz","year":"2004","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib91","doi-asserted-by":"crossref","first-page":"8383","DOI":"10.1128\/JVI.76.16.8383-8399.2002","article-title":"Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells","volume":"76","author":"Moses","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.jaad.2005.02.011_bib92","first-page":"195","article-title":"Imatinab mesylate in AIDS-related Kaposi's sarcoma","volume":"22","author":"Koon","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib93","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaad.2005.02.011_bib94","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2005.02.011_bib95","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaad.2005.02.011_bib96","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2005.02.011_bib97","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2005.02.011_bib98","unstructured":"National Institutes of Health. Therapy of hypereosino philic syndrome, polycythemia vera, atypical CML or CMML with PDGF-R fusion genes, or mastocytosis with Gleevec. Available from: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00038675?order=1. Accessed September 24, 2004."},{"key":"10.1016\/j.jaad.2005.02.011_bib99","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2005.02.011_bib100","first-page":"196","article-title":"Rash severity is predictive of increased survival with erlotinib HCl","volume":"22","author":"Clark","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2005.02.011_bib101","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2005.02.011_bib102","first-page":"187a","article-title":"CCI-779, a rapamycin analog with antitumor activity: a phase I study utilizing a weekly schedule","volume":"19","author":"Raymond","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2005.02.011_bib103","first-page":"414","article-title":"CCI-779, an ester analogue of rapamycin that interacts with PTEN\/PI3 kinase pathways: a phase I study utilizing a weekly intravenous schedule","volume":"6","author":"Raymond","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib104","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJM200208083470614","article-title":"Imatinib mesylate and gray hair","volume":"347","author":"Etienne","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2005.02.011_bib105","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(03)12805-X","article-title":"Tyrosine kinase inhibition and grey hair","volume":"361","author":"Robert","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2005.02.011_bib106","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1158\/0008-5472.CAN-04-0562","article-title":"Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor","volume":"64","author":"Huang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib107","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00062752-200207000-00007","article-title":"Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia","volume":"9","author":"Gorre","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jaad.2005.02.011_bib108","doi-asserted-by":"crossref","first-page":"7756","DOI":"10.1158\/0008-5472.CAN-04-1881","article-title":"Protein kinase C epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas","volume":"64","author":"Wheeler","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2005.02.011_bib109","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/1523-1747.ep12468992","article-title":"Effects of the selective protein kinase C inhibitor, Ro 31-7549, on the proliferation of cultured mouse epidermal keratinocytes","volume":"100","author":"Bollag","year":"1993","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096220500678X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096220500678X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:38:39Z","timestamp":1759268319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096220500678X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S019096220500678X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2005.02.011","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The promise of molecular targeted therapies: Protein kinase inhibitors in the treatment of cutaneous malignancies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2005.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}